Last updated on February 2019

A Phase 3 Randomized Multi-center Double-blinded Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)


Brief description of study

This is a phase 3, randomized, multi-center, double-blinded, active-controlled study that is primarily designed to assess the Annualized Relapse Rate (ARR) and safety/tolerability of ublituximab/oral placebo (TG-1101; UTX) as compared to teriflunomide/ IV placebo in subjects with relapsing MS.

Clinical Study Identifier: NCT03277248

Contact Investigators or Research Sites near you

Start Over

TG Therapeutics Clinical Support Team

TG Therapeutics RMS Investigational Trial Site
Chesterfield, MO United States
0.02miles

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.